Protecting Our Future
ReNewVax
Our aim is to prevent life-threatening bacterial infections and combat antimicrobial resistance with vaccines.
Protecting Our Future Through Vaccine Research
ReNewVax Ltd. is a University of Liverpool spin-out company co-founded by Dr Marie Yang and Prof Aras Kadioglu. The company was created through seed funding awarded by the Innovate ICURe follow on funding and the University of Liverpool’s Enterprise Investment Fund. We aim to prevent life-threatening bacterial infections and combat antimicrobial resistance with heavily tested and researched vaccines.
Vaccine Pipeline
RVX-001
Vaccine to Streptococcus pneumoniae (or pneumococcus)
- ReNewVax Ltd lead program
- A unique proprietary protein-based adjuvanted formulation
- Preclinical POC vs. Prevnar13®(PCV13) and Pneumovax®23 (PPV23) ongoing
- Anticipate Phase 1 top line immunogenicity, safety and tolerability results in adults by end of 2025
RVX-002
Vaccine to Streptococcus agalactiae (or GBS)
- A rationally-designed vaccine formulation based on the analysis of over 15,000 publicly available genomes
- Initiated IND-enabling activities in Q1 2021
- Supported with grant from UKRI-GCRF networking grants
RVX-003
Vaccine to Streptococcus pyogenes (or GAS)
- Selection of final vaccine candidates expected in Q4 2022
- Anticipate IND-enabling studies in Q1/Q2 2023
Our Latest News
